Carpl

About Carpl

Carpl.ai is an enterprise imaging AI marketplace platform designed to address the growing demand for medical imaging analysis amidst a global shortage of radiologists. Founded in 2018 by Dr. Vidur Mahajan, the company became operational in 2021. The concept for Carpl was developed while Dr. Mahajan was at his family's business, Mahajan Imaging, a prominent radiology service provider in India. His experience there, coupled with an MBA from the Wharton School of Business and a medical background, provided him with deep insights into the diagnostics industry's challenges and opportunities.

The company operates in the healthcare AI market, targeting healthcare providers, hospitals, and research institutions. Its business model centers on providing a vendor-neutral platform that simplifies the access, assessment, and integration of radiology AI applications. Revenue is generated primarily through subscription and licensing fees for its platform, with additional streams from consulting and data monetization. Carpl's platform gives clients a single user interface, a unified data channel, and a single procurement system to interact with a multitude of AI solutions.

Carpl.ai's core offering is a comprehensive marketplace featuring over 175 AI applications from more than 75 vendors. This platform allows healthcare providers to discover, test, validate, and deploy AI tools for medical imaging. A key feature is the ability for institutions to run AI applications on their own datasets for validation before full-scale deployment. The platform includes a universal AI viewer, is infrastructure-agnostic—supporting both on-premise and cloud-based deployments—and integrates seamlessly with existing hospital systems like PACS and RIS. This streamlined approach reduces IT overhead and helps to improve diagnostic accuracy and operational efficiency. In February 2024, the company secured $6 million in a seed funding round led by Stellaris Venture Partners to expand its North American team and further develop its technology. Carpl has also achieved significant regulatory milestones, including FDA 510(k) clearance in May 2024 and the CE mark in October 2024, enabling expansion into European markets.